{rfName}
De

Indexed in

License and use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Garcia-Pavia PAuthorFuster VAuthor

Share

April 29, 2020
Publications
>
Article

Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

Publicated to:JACC Basic Transl Sci. 5 (4): 317-327 - 2020-01-01 5(4), DOI: 10.1016/j.jacbts.2020.01.009

Authors: Garcia-Lunar I; Blanco I; Fernández-Friera L; Prat-Gonzàlez S; Jordà P; Sánchez J; Pereda D; Pujadas S; Rivas M; Solé-Gonzalez E; Vázquez J; Blázquez Z; García-Picart J; Caravaca P; Escalera N; Garcia-Pavia P; Delgado J; Segovia-Cubero J; Fuster V; Roig E; Barberá JA; Ibanez B; García-Álvarez A

Affiliations

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) - Author
Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias - Author
Centro Nacional de Investigaciones Cardiovasculares Carlos III - Author
Francisco de Vitoria University - Author
HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM-CIEC - Author
Hospital del Mar - Author
Hospital Universitario 12 de octubre - Author
Hospital Universitario Fundacion Jimenez Diaz - Author
Hospital Universitario Puerta de Hierro - Author
Icahn School of Medicine at Mount Sinai - Author
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS - Author
Philips Healthcare Nederland - Author
Universidad Europea de Madrid - Author
Universitat Autònoma de Barcelona - Author
Universitat de Barcelona - Author
See more

Abstract

© 2020 The Authors Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539)

Keywords

adrenoreceptorscct, cardiac computed tomographycgmp, cyclic guanosine monophosphatecmr, cardiac magnetic resonancecpcph, combined pre- and post-capillary pulmonary hypertensionecg, electrocardiographyhf, heart failureimagingipcph, isolated post-capillary pulmonary hypertensionitt, intention to treatlhd, left heart diseaselv, left ventricularlvef, left ventricular ejection fractionnt-probnp, n-terminal prohormone of brain natriuretic peptidenyha, new york heart associationpap, pulmonary artery pressureph, pulmonary hypertensionpp, per protocolpulmonary hypertensionpvr, pulmonary vascular resistancerv, right ventricletreatment?3ar, beta-3 adrenoreceptorAdrenoreceptorsImagingPulmonary hypertensionTreatmentΒ3ar, beta-3 adrenoreceptor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal JACC Basic Transl Sci due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Cardiology and Cardiovascular Medicine. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.89. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.06 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 7.67 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-16, the following number of citations:

  • WoS: 13
  • Scopus: 15
  • Europe PMC: 7

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 44.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 49 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 12.3.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 22 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/693269

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Netherlands; United States of America.